New allergy shot shows promise in early trial
NCT ID NCT07052097
First seen Feb 13, 2026 · Last updated Jun 20, 2026 · Updated 16 times
Summary
This Phase 2 trial tested an injection called TQC2938, a humanized monoclonal antibody, in 136 adults with seasonal allergic rhinitis. All participants also used a standard nasal spray. The study measured how well the injection reduced nasal symptoms like sneezing and congestion over 2 and 4 weeks compared to a placebo. The trial is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Affiliated Zhongshan Hospital Of Dalian university
Dalian, Liaoning, 116001, China
-
Baotou Central Hospital
Baotou, Inner Mongolia, 14000, China
-
Beijing TongRen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100730, China
-
Cangzhou central hosipital
Cangzhou, Hebei, 061000, China
-
China-japan Friendship Hospital, Jilin University
Changchun, Jilin, 130033, China
-
First Affiliated Hospital, Heilongjang University of Chinese Medigine
Harbin, Heilongjang, 150040, China
-
First Hospital of Shangxi Medical University
Taiyuan, Shangxi, 30001, China
-
Ganzu Province People's Hospital
Lanzhou, Ganzu, 730000, China
-
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750004, China
-
Hebei Medical University Third Hospital
Shijiazhuang, Hebei, 050000, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450002, China
-
Northern Jiangsu People'S Hospital
Yangzhou, Jiangsu, 225000, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
People'S Hospital of Zhengzhou
Zhengzhou, Henan, 450002, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250021, China
-
Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710004, China
-
Shanxi Bethune Hospital
Taiyuan, Shanxi, 030000, China
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110004, China
-
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650032, China
-
The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
Xi'an, Shaanxi, 710089, China
-
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830013, China
-
The Second People's Hospital of Shandong Province
Jinan, Shandong, 250021, China
-
The first hospital of Jilin University
Changchun, Jilin, 130031, China
-
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, 300192, China
-
Tongji Hospital of Tongji medical college of HUST
Wuhan, Hubei, 430030, China
-
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
-
Zhengzhou Central Hospital
Zhengzhou, Henan, 450007, China
-
Zibo Central Hospital
Zibo, Shandong, 255020, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQC2938 injection (a humanized monoclonal antibody)
What this could lead to
If it works, this could provide a new add-on treatment option for people with seasonal allergies who still have symptoms despite using standard nasal sprays.
What could go wrong
This is an early Phase 2 trial with only 136 participants, so results may not apply to everyone. The drug is still experimental and may not prove more effective than placebo.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.